Traders should monitor upcoming Phase 2b trial initiation and design details, as well as competitive dynamics with faricimab (VEGF-A/ANG-2 inhibitor from Roche). Positive Phase 3 readout could significantly re-rate NBP stock; consider positioning ahead of clinical milestones.
Price Chart
Executive Summary
NovaBridge Biosciences announced positive topline Phase 2a results for VIS-101, a dual VEGF-A X ANG-2 inhibitor, showing rapid, robust, and durable treatment responses in wet AMD with mean BCVA gains >10 ETDRS letters and median CST reductions of 100–150 µm. Nearly half of patients remained retreatment-free at 6 months, with a favorable safety profile and no dose-limiting toxicity. The data support advancement to a Phase 2b study in H2 2026 and a global Phase 3 program in 2027.
Key Facts
- VIS-101 demonstrated mean BCVA improvement of >10 ETDRS letters in wet AMD patients
- Median CST reduction of 100–150 µm observed
- Approximately two-thirds of patients were retreatment-free at 4 months; half at 6 months
- No dose-limiting toxicity; 0% treatment-related adverse events in 3 mg group, 8% in 6 mg group
- Phase 2b dose-finding study expected to begin in H2 2026, global Phase 3 in 2027
Financial Impact
Potential blockbuster value given best-in-class durability profile in a $10B+ ophthalmology market; could command premium pricing and high market share if Phase 3 confirms results
Risk Factors
- Phase 2a was small (n=38) and conducted only in China; results may not replicate in larger, global populations
- No direct comparison to current standard-of-care (e.g., faricimab) in the trial
- Regulatory path remains uncertain; Phase 3 design and endpoints not yet disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251682 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.22 | awaiting T+5 | — | $1.25 (+3.29%) |
Oct 25, 2026 2d ago | Press Release | $1.22 | awaiting T+5 | — | $1.25 (+3.29%) |
Oct 23, 2026 4d ago | 6-K | $1.37 | awaiting T+5 | — | $1.25 (−8.39%) |
Oct 13, 2026 14d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.25 (−2.71%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.25 (−34.29%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.25 (−29.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers